Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
Clinical trial NCT06998173 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06998173
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-31
- Primary completion
- 2026-12-30
- Enrollment
- 228
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.